The contractor shall produce 20 liters of clinical-grade gamma-retroviral gene-therapy vector for use in a clinical trial. This gamma-retroviral gene-therapy vector will be produced by the transient…
Ended Purchase Order Awarded Last action
- Contract number
- HHSN261201700263P
- Awardee
-
Childrens Hospital Medical Center UEI JZD1HLM2ZU83
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $258,310
Award facts
- Opportunity
-
- N02RC7253688 Solicitation number
- Production of Clinical-grade Gamma-retrovirus vector encoding an anti-CD319 Chimeric Antigen Receptor Award Notice · Posted Aug 14, 2017
- Production of clinical-grade gamma-retrovirus vector encoding an anti-CD319 chimeric antigen receptor Award Notice · Posted Apr 6, 2017
- Contract value 100% obligated
- $258,310.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20892, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $258,310 |
About this award
The National Cancer Institute awarded a purchase order to Children's Hospital Medical Center valued at $258,310 on August 11, 2017, for the production of 20 liters of clinical-grade gamma-retroviral gene-therapy vector. Work is performed in Bethesda, Maryland. The vector, produced by transient transfection method in 293T cells and GALV-pseudotyped, encodes a chimeric antigen receptor targeting multiple myeloma antigen for use in a clinical trial to transduce patient T cells as a multiple myeloma treatment. The contractor provides packaging plasmids; NCI provides the expression construct. The contract is firm fixed price with an ultimate completion date of June 1, 2018, and includes a no-cost extension.
Description
The contractor shall produce 20 liters of clinical-grade gamma-retroviral gene-therapy vector for use in a clinical trial. This gamma-retroviral gene-therapy vector will be produced by the transient transfection method, and the vector must be completed by the end of 2017. The vector will encode a chimeric antigen receptor (car) recognizing a multiple myeloma antigen. The intended use of this vector is to transduce patient T cells. These T cells will be administered as a treatment for multiple myeloma in a clinical trial. The vector will be gibbon APE leukemia virus (GALV) pseudotyped. The vector will be generated in 293T cells. The contractor will provide packaging plasmids. The NCI will provide a plasmid encoding the car also known as the expression construct.
Quick answers
Who was awarded contract HHSN261201700263P?
HHSN261201700263P was awarded to Childrens Hospital Medical Center by National Cancer Institute (National Institutes of Health) on August 11, 2017.
How much is contract HHSN261201700263P worth?
The government has obligated $258,310 on HHSN261201700263P.
Was contract HHSN261201700263P competed?
The extent of competition for HHSN261201700263P was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award